J&J's Invega Will Launch In January As Follow-On To Risperdal
This article was originally published in The Pink Sheet Daily
Executive Summary
Paliperidone is the first atypical antipsychotic to be approved since 2003.
You may also be interested in...
J&J Files NDA For Once-Monthly Dose Of Invega
Company is seeking approval of long-acting injectable paliperidone in schizophrenia.
J&J Files NDA For Once-Monthly Dose Of Invega
Company is seeking approval of long-acting injectable paliperidone in schizophrenia.
Early Adoption Of Invega Less “Robust” Than Anticipated, J&J Says
Atypical antipsychotic has a 4.4 percent share of the churn market for schizophrenia drugs since launch, firm reports.